tldrdailynews.com logo

Vertex's Pain Drug Failures and Leadership Changes Shake Investor Confidence

1 min read
Source: statnews.com
Vertex's Pain Drug Failures and Leadership Changes Shake Investor Confidence
Photo: statnews.com
TL;DR

Vertex Pharmaceuticals announced that its experimental pain drug VX-993 failed to outperform placebo in a Phase 2 trial, leading to the discontinuation of its development as a single-agent for acute pain, though the company will continue testing it for chronic nerve pain in diabetic patients.

Topics:businesshealth#drug-development#health#pain-relief#phase-2-trial#vertex-pharmaceuticals#vx-993
Share this article
  1. Vertex next-generation pain candidate fails Phase 2 trial  statnews.com
  2. Vertex Stock Falls After Pain-Drug Setback, Despite Stronger Earnings  The Wall Street Journal
  3. Vertex Stock Tumbles 15% After Strong Earnings. What’s Spooking Investors.  Barron's
  4. Vertex’s top scientist Altshuler to retire, next-generation pain drug fails  Endpoints News
  5. Vertex's trial failure, scrapped study cloud pain drug push; shares slump  Reuters

Want the full story? Read the original reporting

Read on statnews.com